CoChat
Sign Up
Cited by 232Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and LipoproteinsPharmacology and Obesity Treatment

The DOI matches its Crossref record; 64 of the 65 references it cites were found in a registry or an index.

Effect of Glucagon-like Peptide-1 Receptor Agonists on Lipid Profiles Among Type 2 Diabetes: A Systematic Review and Network Meta-analysis

Sun, Feng, Wu, Shanshan, Wang, Jing, Guo, Shuxia, Chai, Sanbao, Yang, Zhirong, Li, Lishi, Zhang, Yuan, Ji, Linong, Zhan, Siyan·2015·Clinical Therapeutics
DOI 10.1016/j.clinthera.2014.11.008
Open this paper in CoChat — free account

Abstract

Purpose The goal of this study was to assess the effect of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) on lipid profiles in patients with type 2 diabetes. Methods The MEDLINE, Embase, Cochrane Library, and ClinicalTrials.gov databases were searched from inception through October 31, 2013. Randomized controlled trials with available data were selected if they compared GLP-1 RAs with placebo and traditional antidiabetic drugs with a duration ≥8 weeks. The weighted mean difference for changes in lipid profiles was estimated by using the random effects model, and a network meta-analysis was performed to supplement direct comparisons. Findings Thirty-five trials with 13 treatments were included in the analysis. GLP-1 RAs decreased HDL-C with a range of -0.06 mmol/L (95% CI, -0.11 to -0.01) to -0.13 mmol/L (95% CI, -0.17 to -0.10) compared with thiazolidinediones, whereas thiazolidinediones were associated with a significant increase in HDL-C compared with placebo (0.09 mmol/L [95% CI, 0.06 to 0.12]). A significant reduction in LDL-C was detected for all GLP-1 RAs versus placebo (range, -0.08 to -0.16 mmol/L), insulin (range, -0.10 to -0.19 mmol/L), and thiazolidinediones (range, -0.16 to -0.24 mmol/L). Exenatide, liraglutide 1.8 mg once daily, and taspoglutide decreased total cholesterol with a range of -0.16 mmol/L (95% CI, -0.26 to -0.06) to -0.27 mmol/L (95% CI, -0.41 to -0.12) versus placebo and thiazolidinediones (range, -0.26 to -0.37 mmol/L). The decreased effect was more evident in exenatide long-acting release and liraglutide 1.8 mg once daily. A significant reduction in triglyceride levels was observed with liraglutide 1.8 mg once daily (-0.30 mmol/L [95% CI, -0.49 to -0.11]) and taspoglutide 20 mg once weekly (-0.17 mmol/L [95% CI, -0.31 to -0.01]) versus placebo. Implications GLP-1 RAs were associated with modest reductions in LDL-C, total cholesterol, and triglycerides but no significant improvement in HDL-C. Further evidence is needed to determine if improvements in lipid profiles might translate into reductions in cardiovascular outcomes.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.clinthera.2014.11.008

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 65 references

Research works printed but not linked: 2

  1. Plutzky, 2009, A meta-analysis demonstrates that liraglutide, a once-daily human GLP-1 analogue significantly reduces lipids and other markers of cardiovascular risk in type 2 diabetes, Diabetologia, 52, S299
  2. Simo, 2012, Long-term administration of exenatide and changes in body weight and markers of cardiovascular risk: a comparative study with glimepiride (abstract 781), Diabetologia, 55, S332

Cited by

Sorted by citations

Items 201–232 of 232

Related

See all

Metadata

Authors
Sun, F., Wu, S., Wang, J., Guo, S., Chai, S., Yang, Z., Li, L., Zhang, Y., Ji, L., & Zhan, S.
Affiliations
  • Shihezi University (CN)
  • Peking University (CN)
  • Capital Medical University (CN)
Corresponding author
Zhan, Siyan
ORCID
Venue
Clinical Therapeutics
Publisher
Elsevier BV
Published
2015-01
Volume
37
Issue
1
Pages
225-241.e8
ISSN
0149-2918 (ISSN-L)
DOI
10.1016/j.clinthera.2014.11.008
OpenAlex
W2072750268
Cited by
232
References
65
Citations by year
2026: 21 · 2025: 25 · 2024: 30 · 2023: 17 · 2022: 21 · 2021: 24 · 2020: 24 · 2019: 17 · 2018: 12 · 2017: 17 · 2016: 19 · 2015: 5
FWCI
2.18
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • Clinical Therapeutics (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Wellcome Trust (089276)
  • National Natural Science Foundation of China
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
GLP-1 receptor agonists, type 2 diabetes, lipid profile, HDL cholesterol, LDL cholesterol, total cholesterol, triglycerides, exenatide, liraglutide, thiazolidinediones, insulin, cardiovascular risk, dyslipidemia
MeSH terms
Liraglutide, Exenatide, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin, Lipids, Peptides, Venoms, Thiazolidinediones, Incretins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review